| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.IJPHARM.2007.12.016 |
| P8608 | Fatcat ID | release_znqwbw2n3jd25cpideugbmc2ie |
| P698 | PubMed publication ID | 18242896 |
| P2093 | author name string | Lei Gao | |
| Minghui Chen | |||
| Cunxian Duan | |||
| Dianrui Zhang | |||
| Lejiao Jia | |||
| Wenfa Zhao | |||
| Wenting Dai | |||
| P433 | issue | 1-2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 321-327 | |
| P577 | publication date | 2007-12-23 | |
| P1433 | published in | International Journal of Pharmaceutics | Q6051539 |
| P1476 | title | Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions | |
| P478 | volume | 355 |
| Q37970772 | A mini review of nanosuspensions development |
| Q38985268 | A recent trend of drug-nanoparticles in suspension for the application in drug delivery. |
| Q38052827 | Application of drug nanocrystal technologies on oral drug delivery of poorly soluble drugs |
| Q38151736 | Availability of polymeric nanoparticles for specific enhanced and targeted drug delivery |
| Q37455236 | Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug delivery |
| Q37491804 | Buparvaquone loaded solid lipid nanoparticles for targeted delivery in theleriosis |
| Q38570503 | Developing nanocrystals for cancer treatment. |
| Q28387804 | Discovery and development of natural product oridonin-inspired anticancer agents |
| Q47433211 | Drug nanocrystals for cancer therapy |
| Q26744024 | Drug nanocrystals: A way toward scale-up |
| Q43173878 | Effect of the excipient concentration on the pharmacokinetics of PM181104, a novel antimicrobial thiazolyl cyclic peptide antibiotic, following intravenous administration to mice |
| Q54246268 | Effects of Oridonin on growth performance and oxidative stress in broilers challenged with lipopolysaccharide. |
| Q33735835 | Effects of oridonin nanosuspension on cell proliferation and apoptosis of human prostatic carcinoma PC-3 cell line |
| Q35284235 | Elucidating the in vivo fate of nanocrystals using a physiologically based pharmacokinetic model: a case study with the anticancer agent SNX-2112. |
| Q41103685 | Folate-modified Annonaceous acetogenins nanosuspensions and their improved antitumor efficacy |
| Q35122772 | Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery |
| Q39629849 | Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by oridonin nanosuspension |
| Q36951503 | In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer |
| Q26752396 | Injected nanocrystals for targeted drug delivery |
| Q61813075 | Interactions of Self-Assembled S Polysaccharide Nanoparticles with Bovine Serum Albumin and Biodistribution of Its Docetaxel-Loaded Nanoparticles |
| Q37682912 | Lymph cancer chemotherapy: delivery of doxorubicin-gemcitabine prodrug and vincristine by nanostructured lipid carriers |
| Q36010319 | Modification of paclitaxel-loaded solid lipid nanoparticles with 2-hydroxypropyl-β-cyclodextrin enhances absorption and reduces nephrotoxicity associated with intravenous injection |
| Q38104343 | Nanocrystals for the parenteral delivery of poorly water-soluble drugs |
| Q58726467 | Nanocrystals of Poorly Soluble Drugs: Drug Bioavailability and Physicochemical Stability |
| Q33728156 | Nanocrystals of a new camptothecin derivative WCN-21 enhance its solubility and efficacy |
| Q37953309 | Nanomedicine: evolutionary and revolutionary developments in the treatment of certain inflammatory diseases |
| Q59113220 | Nanosuspension Technologies for Delivery of Poorly Soluble Drugs |
| Q40020400 | Nanosuspension formulations of poorly water-soluble compounds for intravenous administration in exploratory toxicity studies: in vitro and in vivo evaluation |
| Q46814392 | Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation |
| Q35577252 | Nitrendipine nanocrystals: its preparation, characterization, and in vitro-in vivo evaluation |
| Q34278726 | Oridonin nanosuspension was more effective than free oridonin on G2/M cell cycle arrest and apoptosis in the human pancreatic cancer PANC-1 cell line |
| Q91670672 | Parenteral nanosuspensions: a brief review from solubility enhancement to more novel and specific applications |
| Q33709579 | Preclinical studies of N₃-O-toluyl-fluorouracil-loaded lipid-based nanosuspensions in H₂₂-bearing mice |
| Q35179026 | Preparation and evaluation of quercetin-loaded lecithin-chitosan nanoparticles for topical delivery |
| Q43859100 | Preparation and in vitro/in vivo evaluation of felodipine nanosuspension |
| Q100945795 | Preparation of parenteral nanocrystal suspensions of etoposide from the excipient free dry state of the drug to enhance in vivo antitumoral properties |
| Q43025626 | Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer |
| Q40575295 | RGD-modified poly(D,L-lactic acid) nanoparticles enhance tumor targeting of oridonin |
| Q92702276 | Solubility and Bioavailability Enhancement of Oridonin: A Review |
| Q93238426 | State of the Art of Pharmaceutical Solid Forms: from Crystal Property Issues to Nanocrystals Formulation |
| Q34102022 | Studies on pharmacokinetics and tissue distribution of bifendate nanosuspensions for intravenous delivery |
| Q61947589 | Therapeutic Potential of Oridonin and Its Analogs: From Anticancer and Antiinflammation to Neuroprotection |
Search more.